- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What Is and Is Not in Trump's Drug Pricing Plan: An Interview With Dr Michael Chernew
American Patients First, President Donald Trump's blueprint to bring down the cost of drug pricing is the result of a campaign promise to drive down out-of-pocket costs for consumers. Those who helped craft the proposal say it represents real reform. However, critics say it goes too easy on the pharmaceutical industry.
American Patients First, President Donald Trump's blueprint to bring down the cost of drug pricing is the result of a campaign promise to drive down out-of-pocket costs for consumers. Those who helped craft the proposal say it represents real reform. However, critics say it goes too easy on the pharmaceutical industry.
Mary Caffrey, the managing editor of The American Journal of Managed Care® (AJMC®)’s Evidence-Based series, spoke with Harvard healthcare economist Michael E. Chernew, PhD, who is the co-editor in chief of AJMC®, to discuss elements of the Trump administration proposal to control drug prices. Chernew is also a former vice chair of the Medicare Payment Advisory Commission.
To listen, login to the website.
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Listen above or through one of these podcast services:
Read more:
Trump Offers Blueprint to Drive Down Prescription Drug Prices; Targets Rebates, "Middlemen"
Azar Stumps for Plan to Hold Down Prescription Drug Costs
Trump Targets Drug Prices, Right-to-Try in State of the Union
